Efavirenz: A Comprehensive Pharmacology Review for Clinicians

Efavirenz has been a cornerstone of first‑line antiretroviral therapy for over two decades, yet its use remains a balancing act between efficacy and neuropsychiatric toxicity. In a recent cohort of 1,200 HIV‑positive adults initiating efavirenz‑based regimens, 38 % reported vivid dreams or anxiety within the first month, underscoring the drug’s impact on the central nervous system. Understanding the pharmacologic nuances that drive both its antiviral potency and adverse effect profile is essential for clinicians who must tailor therapy to diverse patient populations, from infants to pregnant women. This review dissects efavirenz’s mechanism of action, pharmacokinetics, therapeutic indications, safety considerations, and exam‑relevant pearls to equip pharmacy and medical students with a comprehensive knowledge base.

Introduction and Background

Efavirenz (EFV) belongs to the non‑nucleoside reverse transcriptase inhibitor (NNRTI) class, first approved by the FDA in 1998 for treatment‑naïve adults with HIV‑1 infection. The drug was designed to bind covalently to the allosteric pocket of the HIV‑1 reverse transcriptase (RT) enzyme, thereby preventing the conversion of viral RNA into DNA. Since its introduction, efavirenz has been incorporated into numerous fixed‑dose combination (FDC) tablets, such as Atripla and Symmetrel, enabling once‑daily dosing and improving adherence in resource‑limited settings.

Clinically, efavirenz remains a preferred agent in many first‑line regimens, particularly in low‑ and middle‑income countries where drug availability and cost are critical considerations. However, its neuropsychiatric side effect profile has limited its acceptability in certain populations, prompting the development of newer NNRTIs with improved tolerability. Epidemiologically, the prevalence of efavirenz use has declined in high‑income countries but remains high in sub‑Saharan Africa, where the drug’s affordability and once‑daily dosing confer significant public health benefits.

The pharmacologic background of efavirenz is intertwined with its metabolism by cytochrome P450 2B6 (CYP2B6), a polymorphic enzyme that leads to inter‑individual variability in plasma concentrations and toxicity risk. This variability underscores the importance of genotype‑guided dosing and monitoring in clinical practice.

Mechanism of Action

Inhibition of HIV Reverse Transcriptase

Efavirenz binds to a hydrophobic pocket adjacent to the active site of HIV‑1 reverse transcriptase, forming a non‑covalent, yet highly stable interaction that sterically hinders the polymerase activity. Unlike nucleoside analogues that compete with natural nucleotides, efavirenz’s binding induces a conformational shift that prevents the correct positioning of the viral RNA template and deoxynucleotide triphosphates, effectively halting DNA synthesis. The drug’s high affinity (K_d≈10 nM) for the RT pocket translates into potent antiviral activity, with an in vitro 50 % inhibitory concentration (IC₅₀) of 0.5 nM.

Structural Considerations and Binding Pocket Interactions

Crystal structure analysis reveals that efavirenz engages multiple hydrophobic residues, including Val106, Val108, and Tyr181, and forms a hydrogen bond with Asp110. These interactions stabilize the drug within the pocket and prevent the RT from adopting the “open” conformation necessary for catalysis. Importantly, efavirenz’s binding is highly selective for the HIV‑1 RT, sparing human DNA polymerases and thereby reducing off‑target toxicity. However, the drug’s lipophilicity (log P≈4.4) facilitates passive diffusion across the blood‑brain barrier, contributing to both its therapeutic effect against viral reservoirs in the central nervous system and its neuropsychiatric adverse events.

Clinical Pharmacology

Efavirenz is administered orally as a 600 mg tablet once daily, with or without food. The drug’s absolute bioavailability is high (> 90 %) and absorption is rapid, reaching peak plasma concentrations (C_max) 2–4 hours post‑dose in fasted adults. The apparent volume of distribution is extensive (≈ 200 L), reflecting extensive tissue penetration, including the central nervous system. Metabolism is primarily mediated by CYP2B6, producing the 8‑hydroxy efavirenz metabolite; CYP2D6 and CYP3A4 contribute modestly. The terminal half‑life ranges from 25 to 40 hours, supporting once‑daily dosing. Excretion occurs mainly via feces (≈ 70 %) with a minor urinary component (≈ 30 %).

The pharmacodynamic relationship between plasma concentration and viral suppression is dose‑dependent, with therapeutic trough concentrations (C_trough) ≥ 1 µg/mL associated with > 90 % virologic response. However, higher concentrations (> 5 µg/mL) correlate with increased neuropsychiatric toxicity. Genotype‑guided dosing, particularly for CYP2B6 516G>T polymorphism, can reduce the risk of elevated plasma levels and associated adverse events.

Therapeutic Applications

• HIV‑1 infection (treatment‑naïve): 600 mg once daily in combination with tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) as part of a fixed‑dose combination.
• HIV‑1 infection (treatment‑experienced): 600 mg once daily with an integrase strand transfer inhibitor (INSTI) or protease inhibitor (PI) backbone.
• Pre‑exposure prophylaxis (PrEP) – investigational: 600 mg once daily under clinical trial protocols; not approved for PrEP.
• Special population – pediatric: Weight‑based dosing of 10 mg/kg once daily (max 600 mg) for children ≥ 10 kg; approved for ages 2–12 years in certain regions.
• Special population – geriatric: Standard 600 mg once daily; no dose adjustment required.
• Special population – renal impairment: No adjustment; efavirenz is not a substrate for renal transporters.
• Special population – hepatic impairment: In severe hepatic dysfunction (Child‑Pugh C), reduce dose to 300 mg once daily; monitor liver enzymes closely.
• Special population – pregnancy: Category C; use only if benefits outweigh risks; avoid first trimester if possible; monitor fetal development.

Adverse Effects and Safety

Common neuropsychiatric adverse events occur in 30–50 % of patients and include vivid dreams (≈ 30 %), dizziness (≈ 20 %), headache (≈ 15 %), and ataxia (≈ 10 %). Serious CNS events such as psychosis or suicidal ideation are rare (< 1 %) but warrant immediate evaluation. Dermatologic reactions, including maculopapular rash (≈ 5 %) and Stevens‑Johnson syndrome (≈ 0.1 %) are also notable.

Hepatotoxicity manifests as transaminitis in 5–10 % of patients, with severe hepatic failure reported in < 0.5 % of cases. The black box warning highlights the risk of severe neuropsychiatric toxicity and the potential for suicide ideation, emphasizing the need for thorough patient counseling and monitoring.

Drug interactions are driven by efavirenz’s induction of CYP3A4 and inhibition of CYP2B6. Key interactions include:

Monitoring parameters include baseline and periodic liver function tests (ALT, AST), complete blood count, and neuropsychiatric assessment. Contraindications encompass hypersensitivity to efavirenz, severe hepatic impairment (Child‑Pugh C), and concomitant use of strong CYP2B6 inhibitors that cannot be avoided.

Clinical Pearls for Practice

• Genotype‑guided dosing: Patients with CYP2B6 516G>T homozygous variant can experience 3–4× higher trough levels; consider dose reduction to 300 mg or therapeutic drug monitoring.
• Neuropsychiatric counseling: Discuss vivid dreams and mood changes before initiation; schedule follow‑up within 2 weeks to assess tolerance.
• Pregnancy considerations: Avoid efavirenz in the first trimester when possible; if unavoidable, weigh the risk of neurotoxicity against uncontrolled HIV progression.
• Drug interaction vigilance: Review concomitant medications for CYP3A4 inducers; adjust efavirenz dose accordingly or switch to a non‑inducing antiretroviral.
• Monitoring liver enzymes: Check ALT/AST at baseline, week 4, and every 3 months thereafter; consider dose adjustment if > 5× ULN.
• Fixed‑dose combinations: Atripla (EFV/TDF/FTC) simplifies adherence but requires careful monitoring of renal function for TDF component.
• Adverse event triage: If rash develops, evaluate severity; mild rash may resolve with antihistamines, but severe rash warrants discontinuation.

Comparison Table

Exam‑Focused Review

USMLE Step 2/Step 3 and NAPLEX frequently test efavirenz knowledge through clinical vignettes. Common question stems include:

• Vivid dreams and anxiety in a 28‑year‑old HIV‑positive patient: Which antiretroviral is most likely responsible? (Answer: Efavirenz)
• Child with CYP2B6 516G>T homozygous variant develops CNS toxicity on standard efavirenz dose: What adjustment should be made? (Answer: Reduce dose to 300 mg or switch to another NNRTI)
• Pregnant woman in her first trimester requiring antiretroviral therapy: Which agent should be avoided? (Answer: Efavirenz due to teratogenic risk)
• Co‑administration of rifampin and efavirenz leads to subtherapeutic viral loads: What is the most appropriate intervention? (Answer: Increase efavirenz dose or switch to a different antiretroviral not induced by rifampin)

Key differentiators students often confuse include:

• Efavirenz vs. Nevirapine: Both NNRTIs, but efavirenz has CNS toxicity while nevirapine presents with hepatotoxicity and rash.
• Efavirenz vs. Lopinavir/ritonavir: Efavirenz is an NNRTI with once‑daily dosing; lopinavir/ritonavir is a PI requiring twice‑daily dosing and has significant GI side effects.
• CYP2B6 polymorphism impact: Only efavirenz metabolism is heavily influenced by CYP2B6; other NNRTIs rely more on CYP3A4.

Must‑know facts:

1. Standard dose: 600 mg once daily.
2. Peak concentration: 2–4 hours post‑dose.
3. Half‑life: 25–40 hours.
4. Black box warning for neuropsychiatric toxicity.
5. Contraindicated in severe hepatic impairment (Child‑Pugh C).
6. Pregnancy category C; avoid first trimester if possible.
7. Genotype screening for CYP2B6 516G>T can guide dose adjustment.
8. Efavirenz induces CYP3A4, increasing metabolism of many concomitant drugs.

Key Takeaways

1. Efavirenz is a first‑line NNRTI with potent antiviral activity and once‑daily dosing.
2. High lipophilicity enables CNS penetration, accounting for both efficacy against viral reservoirs in the central nervous system and neuropsychiatric toxicity.
3. Metabolism is dominated by CYP2B6; polymorphisms significantly influence plasma levels and adverse event risk.
4. Standard adult dose is 600 mg once daily; pediatric dosing is weight‑based (10 mg/kg, max 600 mg).
5. Neuropsychiatric side effects (vivid dreams, anxiety, depression) occur in 30–50 % of patients.
6. Hepatotoxicity and rash are less common but serious; baseline liver tests are mandatory.
7. Drug interactions via CYP3A4 induction (rifampin) or inhibition (cyclosporine) require dose adjustments or alternative agents.
8. Pregnancy category C necessitates careful risk‑benefit assessment; avoid during the first trimester if possible.
9. Therapeutic drug monitoring or CYP2B6 genotyping can reduce toxicity in high‑risk individuals.
10. Efavirenz remains a key component of affordable, once‑daily regimens, especially in resource‑limited settings.

Remember: efavirenz’s therapeutic promise is matched by its neuropsychiatric caution. Early counseling, vigilant monitoring, and individualized dosing are the cornerstones of safe therapy.